PRNewsWire
29 Jul 2026, 09:30 UTC · 2h ago
Dasher Neuroscience completa el reclutamiento de pacientes en el ensayo clínico global de fase 2
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
29 Jul 2026, 09:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Dasher Neuroscience has completed patient recruitment for its global Phase 2 clinical trial of YA-101 for multiple system atrophy (MSA). — Completing recruitment is a major operational milestone that removes a key execution risk and moves the company closer to a data readout.
+0.40Primary clinical results from the YA-101 Phase 2 trial are expected in the first quarter of 2027. — This establishes a specific timeline for the next major binary catalyst that will determine the drug's viability.
+0.30The company is actively seeking global licensing agreements for YA-101 while planning for a Phase 3 trial. — Active pursuit of licensing suggests a goal of non-dilutive funding or a strategic partnership to offset the high costs of Phase 3 development.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
YA-101 has received FDA Fast Track and orphan drug designations in the US, Japan, and the EU. — These designations provide regulatory advantages and potential market exclusivity, though they are common for rare disease candidates.
+0.10Which stocks this story touches
The company successfully completed patient recruitment for its phase 2 clinical trial of its lead drug candidate YA-101.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
14h ago
